CNB0 Stock Overview
A biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.55 |
| 52 Week High | US$16.50 |
| 52 Week Low | US$4.32 |
| Beta | 1.67 |
| 1 Month Change | 3.97% |
| 3 Month Change | 40.56% |
| 1 Year Change | -44.49% |
| 3 Year Change | -70.76% |
| 5 Year Change | n/a |
| Change since IPO | -69.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| CNB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.1% | 4.0% | 0.7% |
| 1Y | -44.5% | -10.2% | 8.4% |
Return vs Industry: CNB0 underperformed the German Biotechs industry which returned -10.2% over the past year.
Return vs Market: CNB0 underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| CNB0 volatility | |
|---|---|
| CNB0 Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CNB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CNB0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 186 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
Fortress Biotech, Inc. Fundamentals Summary
| CNB0 fundamental statistics | |
|---|---|
| Market cap | €56.79m |
| Earnings (TTM) | -€55.82m |
| Revenue (TTM) | €79.09m |
0.8x
P/S Ratio-1.1x
P/E RatioIs CNB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNB0 income statement (TTM) | |
|---|---|
| Revenue | US$81.50m |
| Cost of Revenue | US$85.67m |
| Gross Profit | -US$4.17m |
| Other Expenses | US$53.35m |
| Earnings | -US$57.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | -5.12% |
| Net Profit Margin | -70.58% |
| Debt/Equity Ratio | -421.8% |
How did CNB0 perform over the long term?
See historical performance and comparisonDividends
16.5%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 23:57 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fortress Biotech, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |